Question 1

What are GLP-1 drugs?

Accepted Answer

GLP-1 drugs are medications that mimic a hormone in the body that regulates appetite and blood sugar levels. They have shown strong results in clinical trials for weight loss and have surged in popularity in recent years. Well-known examples include Wegovy and Zepbound. Without insurance coverage, they can cost hundreds of dollars per month out of pocket.

Question 2

What is a direct-to-consumer telehealth platform?

Accepted Answer

A direct-to-consumer telehealth platform lets patients consult with clinicians online, receive prescriptions, and have treatments delivered directly to them — with no GP referral, insurance pre-authorisation, or pharmacy queue required. Companies like Hims & Hers Health operate this model, making them well-positioned to serve patients who lose employer-sponsored drug coverage.

Question 3

What does "event-driven" investing mean?

Accepted Answer

Event-driven investing means building a portfolio position around a specific, documented policy or market shift rather than a long-term secular trend. In this context, the investment case is tied to a real change in employer healthcare coverage for weight-loss drugs. Because the catalyst is tied to an evolving policy environment, timing and ongoing monitoring matter more than in a traditional buy-and-hold approach.

Question 4

Why is Cigna dropping GLP-1 coverage?

Accepted Answer

Cigna cited the high cost of GLP-1 weight-loss drugs and the availability of alternatives as reasons for removing them from its employee benefit plan from 1 July. The move reflects a broader pressure on employer-sponsored healthcare budgets, and analysts suggest Cigna is unlikely to be the last major insurer to reconsider this coverage.

Question 5

What are the risks of investing in telehealth and digital weight care stocks?

Accepted Answer

The key risks include policy reversal — if GLP-1 drug coverage expands again, the demand tailwind for telehealth alternatives would weaken. Smaller companies in this space are operating in a competitive, capital-intensive market, and not all may survive long enough to benefit from structural demand growth. Regulatory changes around compounding pharmacies, drug pricing, and telehealth reimbursement could also shift the landscape significantly.

Question 6

Is Eli Lilly a good investment if its own drug is losing coverage?

Accepted Answer

It may seem counterintuitive, but Eli Lilly has responded to tightening coverage by building its own direct-to-patient digital health platform, allowing it to compete for out-of-pocket customers directly. As one of the largest pharmaceutical companies in the world, its exposure to any single policy shift is far more limited than smaller telehealth providers. Its scale and diversification across therapeutic areas offer a different, more stable risk profile.

Question 7

How does Teladoc differ from Hims & Hers?

Accepted Answer

Hims & Hers targets consumers directly through a sleek direct-to-consumer model, whereas Teladoc operates across both enterprise and direct-to-consumer channels at scale, serving employers, health plans, and individuals. As employers look for cost-effective virtual care alternatives to replace expensive drug benefits, Teladoc's existing relationships within employer-facing healthcare infrastructure give it a distinct angle of exposure to the same underlying shift.

Question 8

Is now a good time to invest in digital weight management?

Accepted Answer

The article argues that Cigna's coverage cut is a catalyst accelerating a structural shift that was already under way. Rising US healthcare costs and the affordability challenge of weight-loss drugs were already straining employer budgets before this announcement. The coverage gap is growing in real time, and telehealth platforms, direct-to-patient pharmaceutical channels, and digital therapeutics are all competing to fill it — suggesting the opportunity may be timely.

Question 9

What is driving growth in the telehealth weight management market?

Accepted Answer

The primary driver is the growing gap between demand for effective weight-loss treatments and the affordability of those treatments without insurance support. As major employers pare back GLP-1 drug coverage, millions of patients are being redirected towards out-of-pocket alternatives. Telehealth platforms are structurally set up to absorb this demand quickly, with low barriers to access and direct prescription fulfilment.

Question 10

What happens to patients when their GLP-1 coverage is cut?

Accepted Answer

Patients do not simply stop seeking treatment — they look for alternatives. Without employer-sponsored coverage, many turn to direct-to-consumer telehealth platforms, compounding pharmacies, digital therapeutics, or direct-to-patient pharmaceutical channels. This redirection of demand is the core investment thesis explored in the article, as it creates a meaningful and measurable shift in where healthcare spending flows.

Question 11

How can I invest in the digital weight care theme on Nemo?

Accepted Answer

Nemo is an ADGM-regulated platform that offers commission-free investing, AI-powered research tools, and fractional shares starting from just $1. You can explore the full list of stocks in this theme — including detailed company data and analyst ratings — by creating a free account. As with all investments, your capital is at risk and past performance is not a guide to future results.

Question 12

Can I invest in US health stocks with a small amount of money?

Accepted Answer

Yes — through Nemo, you can invest in US stocks and thematic baskets using fractional shares starting from just $1, with no trading commissions. This makes it possible to build diversified exposure across telehealth, pharma, and digital health companies without needing a large upfront sum. Nemo is regulated by the ADGM, providing a trusted and accessible route into thematic investing.

When Insurers Stop Paying, Telehealth Starts Winning

When Insurers Stop Paying, Telehealth Starts Winning

Recent insights

Boeing's F-15 Windfall: What $131 Billion Means for Defence Investors

Broadcom's $60-100bn Debt Gamble: What It Means for AI Chip Investors

Amazon's Drone Gamble: What 500 Cities Means for Investors

Samsung's 15% Foundry Price Hike: Korea's AI Chip Moment

Korea's Labour Peace Dividend: Why the Hyundai Wage Deal Matters to Your Portfolio

The Great Weight Care Corporate Dropout

The side door swings open

The heavyweights refuse to yield

Deep Dive

Market & Opportunity

Key Companies

Primary Risk Factors

Growth Catalysts

How to invest in this opportunity

Frequently Asked Questions

Recent insights

Boeing's F-15 Windfall: What $131 Billion Means for Defence Investors

Broadcom's $60-100bn Debt Gamble: What It Means for AI Chip Investors

Amazon's Drone Gamble: What 500 Cities Means for Investors

Samsung's 15% Foundry Price Hike: Korea's AI Chip Moment

Korea's Labour Peace Dividend: Why the Hyundai Wage Deal Matters to Your Portfolio

Boeing's F-15 Windfall: What $131 Billion Means for Defence Investors

Broadcom's $60-100bn Debt Gamble: What It Means for AI Chip Investors

Amazon's Drone Gamble: What 500 Cities Means for Investors

Samsung's 15% Foundry Price Hike: Korea's AI Chip Moment

Korea's Labour Peace Dividend: Why the Hyundai Wage Deal Matters to Your Portfolio